Clinical Trials
22 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06533059 2026-05-26
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05225428 2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT07114601 2026-05-22
OMNIRAY
Eli Lilly and Company
Phase 1 Recruiting
NCT05056077 2026-05-18
TTBF
University of California, San Francisco
Phase NA Active not recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT06043947 2026-05-15
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
Active not recruiting
NCT06172478 2026-05-15
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 2 Recruiting
NCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT04314401 2026-05-13
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Active not recruiting
NCT04550494 2026-05-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06995898 2026-05-13
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT05645510 2026-05-11
LONGEVITI
University of Alberta
Recruiting
NCT06257264 2026-05-11
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Recruiting
NCT04726319 2026-05-06
FHAMe
University of Toronto
Phase NA Completed
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07387263 2026-05-06
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
Phase NA Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting